Mode
Text Size
Log in / Sign up

Meta-analysis finds no stroke benefit but possible bleeding risk with continued OAC after AF ablationStopping blood thinners after heart rhythm repair does not lower stroke risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that continued OAC after AF ablation showed no stroke benefit and possible bleeding risk in this meta-analysis.

This meta-analysis synthesized data from six studies, comprising four randomized trials and two observational cohorts, to assess the net clinical benefit of continuing long-term oral anticoagulation after successful atrial fibrillation ablation. The primary outcome was net clinical benefit, integrating thromboembolic and bleeding outcomes, with secondary outcomes including stroke, transient ischemic attack, systemic embolism, and major bleeding. The comparator group involved cessation of oral anticoagulation, either by stopping therapy or switching to aspirin.

The analysis found that stroke or transient ischemic attack rates were not significantly different between groups, with an odds ratio of 0.69 and a 95% CI of 0.24-1.99. Systemic embolism also did not differ between groups, with a p-value of 0.12. Major bleeding was numerically higher with continued oral anticoagulation, showing an odds ratio of 2.07 and a 95% CI of 0.88-4.86, though this difference was not statistically significant with a p-value of 0.09.

Net clinical benefit values were more negative or near-neutral with continued oral anticoagulation compared to cessation strategies, which were less negative or marginally positive. The fixed-effect risk difference was +0.00067 with a 95% CI ranging from -0.00279 to +0.00413. The authors note limitations including low absolute event rates and the risk of silent atrial fibrillation recurrence. These factors suggest that practice relevance remains uncertain and further evidence is needed before changing standard management.

People who have heart rhythm repair often wonder if they can stop their blood thinners. A major review looked at six studies involving patients who met standard guidelines for taking oral anticoagulation after catheter ablation. The team compared continuing these blood thinners against stopping them or switching to aspirin.

The results showed that stopping the medication did not lower the risk of stroke or other blood clots. The chance of a major stroke or a transient ischemic attack remained similar whether patients continued treatment or stopped. The risk of systemic embolism also did not differ between the groups.

Bleeding was numerically higher when patients continued the blood thinners, but this difference was not statistically significant. The overall benefit to health was slightly better or neutral with continued treatment. This suggests that stopping the drugs offers no clear advantage for preventing clots.

The review noted that the number of actual events was low in these studies. This means the results come with some uncertainty. Patients should not change their medication without talking to their doctor first.

What this means for you:
Stopping blood thinners after heart rhythm repair did not lower stroke risk.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: The optimal long-term antithrombotic strategy after apparently successful catheter ablation of atrial fibrillation (AF) remains uncertain, particularly in patients who meet conventional guideline thresholds for oral anticoagulation (OAC). OBJECTIVES: To compare continuation versus cessation strategies of long-term OAC after successful AF ablation and to quantify net clinical benefit (NCB) integrating thromboembolic and bleeding outcomes. METHODS: We searched PubMed, Cochrane CENTRAL, and Embase from inception through February 2026 for randomized and comparative observational studies evaluating long-term OAC continuation versus cessation (no OAC and/or switch to aspirin) after successful AF ablation. Risk of bias was assessed using RoB2 for randomized trials and a modified Newcastle-Ottawa Scale (NOS) for observational studies. Random-effects meta-analyses used a restricted maximum likelihood estimator with Hartung-Knapp adjustment. NCB was calculated as: thromboembolic event rate - (1.5 × major bleeding rate). RESULTS: Six studies met the inclusion criteria (four randomized trials and two observational cohorts). Stroke/transient ischemic attack (TIA) events were reported in six studies and were not significantly different between OAC continuation and cessation strategies (OR 0.69; 95% CI 0.24-1.99; p = 0.49). Systemic embolism (three studies) did not differ between groups (p = 0.12). Major bleeding (five studies) was numerically higher with continued OAC but not statistically significant (OR 2.07; 95% CI 0.88-4.86; p = 0.09). In NCB analysis, continued OAC yielded more negative or near-neutral NCB values, whereas, the cessation strategies were less negative or marginally positive; the fixed-effect risk difference in NCB (continued OAC vs cessation) was +0.00067 (95% CI -0.00279 to +0.00413). CONCLUSION: This meta-analysis suggests that after successful AF ablation, continuing OAC does not significantly reduce stroke risk compared to cessation or switching to aspirin, but it may increase major bleeding. While NCB trends favor cessation, the low absolute event rates and the risk of silent AF recurrence necessitate caution.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.